ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Homeostasis of Gut Microbiota Protects against Susceptibility to Fungal Pneumonia.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ozone Exposure Induces Pulmonary Microbiota Dysbiosis and Associated Inflammatory Responses in Mice.Toxics · 2026Article
- Gut mycobiota alteration contributes to the pathogenesis of Pneumocystis pneumonia.Journal of translational medicine · 2026Article
- The potential role of lily polysaccharide in mitigating radiation-induced pneumonitis via the gut-lung axis: a comprehensive review.Frontiers in pharmacology · 2026Review
- Homeostasis of Gut Microbiota Protects against Susceptibility to Fungal Pneumonia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Fungal pneumonia is a serious disease with great harm and high prevalence, presenting significant challenges in diagnosis and treatment. The gut and respiratory microbiota play a critical role in protecting lung health against fungal pneumonia. Here, it is established fungal pneumonia by infection via the sinopulmonary route with Fusarium graminearum (F. graminearum) to investigate the influence of gut microbiota state on susceptibility to fungal pneumonia in BALB/c mice. This findings revealed that F. graminearum spore exposure not only impaired pulmonary clearance mechanisms but also significantly upregulated the expression of proinflammatory cytokines, including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). Moreover, spore invasion led to an increase in Staphylococcus abundance and activation of both triglyceride and galactose metabolic pathways. Antibiotic treatment disrupted the gut and respiratory microbiota, facilitating F. graminearum lung colonization, which is evidenced by elevated inflammatory markers in alveolar fluid and dysregulated lung metabolism. It is demonstrated that the gut microbiota influences susceptibility to fungal pneumonia by acting as an intermediary in the gut-lung axis through the bloodstream, thereby modulating lung metabolism and inflammatory responses. These findings open avenues for novel therapeutic strategies, such as gut microbiota modulation, for the prevention and treatment of fungal pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.